Last reviewed · How we verify

Desvenlafaxine succinate 50mg

Seoul National University Hospital · FDA-approved active Small molecule Quality 5/100

Desvenlafaxine succinate 50mg is a Small molecule drug developed by Seoul National University Hospital. It is currently FDA-approved.

At a glance

Generic nameDesvenlafaxine succinate 50mg
SponsorSeoul National University Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Desvenlafaxine succinate 50mg

What is Desvenlafaxine succinate 50mg?

Desvenlafaxine succinate 50mg is a Small molecule drug developed by Seoul National University Hospital.

Who makes Desvenlafaxine succinate 50mg?

Desvenlafaxine succinate 50mg is developed and marketed by Seoul National University Hospital (see full Seoul National University Hospital pipeline at /company/seoul-national-university-hospital).

What development phase is Desvenlafaxine succinate 50mg in?

Desvenlafaxine succinate 50mg is FDA-approved (marketed).

Related